Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

International Nursing Organizations II

International Nursing Organizations II

The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A ring-like accretion structure in M87 connecting its black hole and jet.

Nature·2023

Same author

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.

NPJ vaccines·2022

Same author

A transformed global enterprise for an HIV vaccine.

Journal of the International AIDS Society·2021

Same author

Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.

Journal of virology·2020

Same author

HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use.

The lancet. HIV·2019

Same author

Recent progress in immune-based interventions to prevent HIV-1 transmission to children.

Journal of the International AIDS Society·2017

Search research articles

Related Experiment Video

Updated: May 9, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Organizing the HIV vaccine development effort.

Yegor Voronin¹, William Snow

¹Global HIV Vaccine Enterprise, New York, New York 10004, USA.

Current Opinion in HIV and AIDS

|August 9, 2013

Summary

Diverse organizational structures and funding models advance HIV preventive vaccine research. Collaborations among these initiatives, largely government and foundation funded, are evolving to expedite development.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Related Experiment Videos

Last Updated: May 9, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Area of Science:

Immunology
Vaccinology
Public Health

Background:

Over three decades, HIV preventive vaccine research and development (R&D) has seen numerous organizational structures and funding mechanisms.
The field's evolution reflects a strong motivation to expedite the development of an effective HIV vaccine.

Purpose of the Study:

To describe and compare the diverse organizational structures and funding mechanisms used in HIV preventive vaccine R&D.
To inform evolving infrastructures and collaborative funding models for HIV vaccine development.

Main Methods:

Analysis of organizational models tried, improved, or abandoned over the past 30 years.
Examination of current initiatives, their organizational signatures, and cross-organizational collaborations.

Main Results:

The field has established a stable set of diverse initiatives with distinct organizational characteristics.
Cross-organizational collaborations are emerging, showing potential for beneficial properties.
HIV vaccine R&D is largely supported by government and foundation funding.

Conclusions:

A variety of customized and inventive organizational approaches have been employed, driven by the need for an HIV vaccine.
No single organizational approach has been universally successful, but a complementary constellation of organizations has emerged.
The Global HIV Vaccine Enterprise represents an innovative, evolving collaboration to catalyze progress in HIV vaccine R&D.